SHANGHAI SHUNYI TRADE CO LTD: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from SHANGHAI SHUNYI TRADE CO LTD?

Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by SHANGHAI SHUNYI TRADE CO LTD (China) whose FDA product code names tirzepatide and retatrutide, on Oct 7, 2026. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Shanghai
FEI numbers on the lines
3047423423
Refused lines
2
Lines with an Import Alert 66-80 API or powder code
1
Drugs named in the product codes
Tirzepatide, Retatrutide
Refusal dates
Oct 7, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether SHANGHAI SHUNYI TRADE CO LTD is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Oct 7, 2026China61PIR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
XXX-0763321-9/1/1
Oct 7, 2026China61PIR78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users.

DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
XXX-0763321-9/1/2

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.2
DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.2
INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.1
WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users.1

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

2 lines from FDA files read Nov 15, 2026.